Technology And Biotech News

OpenAI Acquires Orchestra Bio to Accelerate Drug Development via AI Agents

OpenAI has acquired biotech startup Orchestra Bio to integrate its AI agent technology into Rosalind, a suite of tools for life sciences researchers. The move aims to shorten the 10-15 year drug development timeline by automating tasks like study monitoring and timeline tracking.